课题基金 / 基金详情

Nebraska Center for Molecular Target Discovery and Development

Nebraska Center for Molecular Target Discovery and Development
内布拉斯加州分子靶点发现和开发中心
批准号:
10714236
负责人:
Robert E. Lewis
金额:
$230.25万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
未结题
起止时间:
2018-03-16 至 2028-06-30

项目摘要

项目成果

Robert E. Lewis的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结:总体 内布拉斯加州分子目标发现和开发中心(CMTDD)的目标是建立和 扩展内布拉斯加大学医学中心(UNMC)和 内布拉斯加州大学系统催化识别、验证和开发方法 与临床重要疾病有关的分子靶点的操纵。我们察觉到一种增长 期刊和授权机构对日益复杂的模型系统和数据集的期望。 获取这些系统和生成高内容数据通常需要大量的时间投资 以及对有限的研究资源征税的资金。提升CMTDD研究项目的竞争力 领导(RPL)和其他大学教员在第二阶段,CMTDD最近投资于 开发技术,以提高调查员研究的复杂性,同时最大限度地降低 进入。这些技术:单细胞和空间转录分析,有机物生成和 操纵、抑制和蛋白水解靶向嵌合体(PROTAC)的合成将整合成三个 第2阶段CMTDD核心。这些投资将增强该机构的研究能力,扩大 其教师的翻译能力,促进有前途的新员工的培训、指导和职业发展 ,并有效地推动发现和发展,以改善内布拉斯加州和 这个国家。第二阶段RPL为CMTDD带来了广泛的尖端专业知识。带着指导和准备 使用CMTDD支持的核心,我们的RPL将成为自给自足的教员,对 军警部队未来的成功。我们的第二阶段RPL分享了对基本生物学原理的探索热情 这种不充分的细胞动态平衡以及许多疾病可以有效地分类和表征的信念 通过详细的基因组、遗传和分子分析确定驱动因素和漏洞 将出现独特的治疗方法。为了实现这一愿景,CMTDD将:1)保持行政 核心和指导计划,在年的头四年成功地完成了除一名以外的所有初始RPL 支持;2)通过新建立的最先进的单细胞科学核心提高研究能力 以及空间转录、有机物发育、抑制物和PROTAC的合成和验证;以及3) 提供低成本或免费获得这些技术和试剂,作为一种负担得起的手段,以提高 调查员研究的影响。
英文摘要
Project Summary: Overall The goal of the Nebraska Center for Molecular Target Discovery and Development (CMTDD) is to establish and expand physical and intellectual resources at the University of Nebraska Medical Center (UNMC) and the University of Nebraska system to catalyze the identification, validation, and development of approaches for manipulation of molecular targets implicated in clinically important diseases. We perceive an increasing expectation by journals and granting agencies for progressively sophisticated model systems and data sets. Acquisition of these systems and generation of high-content data often requires a substantial investment in time and money that taxes limited research resources. To enhance the competitiveness of CMTDD Research Project Leaders (RPLs) and other university faculty members during Phase 2, the CMTDD recently invested in the development of technologies to enhance the sophistication of investigator research while minimizing the cost of access. These technologies: single-cell and spatial transcriptomic analysis, organoid generation and manipulation, and inhibitor and proteolysis-targeting chimera (PROTAC) synthesis will be integrated into three Phase 2 CMTDD cores. These investments will enhance the research capabilities of the institution, expand the translational capacity of its faculty, facilitate the training, mentoring, and career advancement of promising new faculty, and efficiently drive discovery and development for the improvement of human health in Nebraska and the nation. Phase 2 RPLs bring a breadth of cutting-edge expertise to the CMTDD. With mentoring and ready access to CMTDD-supported cores, our RPLs will become self-supporting faculty members invaluable to the future success of UNMC. Our Phase 2 RPLs share both a passion for exploration of the basic biologic principles that underly cell homeostasis and a belief that many diseases can be effectively classified and characterized through detailed genomic, genetic, and molecular analyses that identify drivers and vulnerabilities from which will emerge unique therapeutic approaches. To realize this vision, the CMTDD will: 1) maintain an Administrative Core and mentoring program that successfully graduated all but one of its initial RPLs in the first four years of support; 2) increase research capacity through newly established state-of-the-art scientific cores for single-cell and spatial transcriptomics, organoid development, and inhibitor and PROTAC synthesis and validation; and 3) provide low- or no-cost access to these technologies and reagents as an affordable means for increasing the impact of investigator research.
期刊论文(13)
专著(0)
科研奖励(0)
会议论文
Ubiquitin E3 ligase FBXO21 regulates cytokine-mediated signaling pathways, but is dispensable for steady-state hematopoiesis.
泛素 E3 连接酶 FBXO21 调节细胞因子介导的信号通路,但对于稳态造血来说是可有可无的。
DOI: 10.1016/j.exphem.2022.08.002
发表时间: 2022
期刊: Experimental hematology
影响因子: 2.6
作者: [Wittorf,KarliJ, Weber,KasidyK, Swenson,SamanthaA, Buckley,ShannonM]
通讯作者: Buckley,ShannonM
DOI: 10.7554/elife.76497
发表时间: 2022-06-17
期刊: ELIFE
影响因子: 7.7
作者: [Ray, Suhita, Chee, Linda, Zhou, Yichao, Schaefer, Meg A., Naldrett, Michael J., Alvarez, Sophie, Woods, Nicholas T., Hewitt, Kyle J.]
通讯作者: Hewitt, Kyle J.
Isolation and Immunodetection of Enzymatic DNA-Protein Crosslinks by RADAR Assay.
通过 RADAR 测定法分离和免疫检测酶促 DNA-蛋白质交联。
DOI: 10.1007/978-1-0716-3373-1_8
发表时间: 2023
期刊: Methods in molecular biology (Clifton, N.J.)
影响因子: --
作者: [Perry,Megan, Ghosal,Gargi]
通讯作者: Ghosal,Gargi
Interactome Profiling of DNA Damage Response (DDR) Mediators with Immunoprecipitation-Mass Spectrometry.
使用免疫沉淀-质谱法对 DNA 损伤反应 (DDR) 介质进行相互作用组分析。
DOI: 10.1007/978-1-0716-3373-1_12
发表时间: 2023
期刊: Methods in molecular biology (Clifton, N.J.)
影响因子: --
作者: [Law,HenryC-H, Noe,Dragana, Woods,NicholasT]
通讯作者: Woods,NicholasT
7
    Pancreatic cancer variant analysis of the All of Us cohort
    Novel Mechanisms Controlling SCLC Tumor Initiation
    Novel Mechanisms Controlling SCLC Tumor Initiation
    Nebraska Center for Molecular Target Discovery and Development
    海外基金